Juvenile Primary Fibromyalgia Syndrome Medication
- Author: Angelo P Giardino, MD, PhD, MPH; Chief Editor: Lawrence K Jung, MD more...
Medication Summary
Pharmacologic treatment of juvenile primary fibromyalgia syndrome (JPFS) is inferred from what has been studied and used in adult fibromyalgia. Typical medication regimens for pediatric fibromyalgia syndrome (FMS) primarily include skeletal muscle relaxants, low-dose tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs). Some evidence reports that pain and symptom management with nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with antidepressants and nonaddictive analgesics is effective.
Antidepressants
Class Summary
Antidepressant agents help decrease pain intensity and improve sleep quality. They counteract the hyperarousal mechanism in FMS and promote deeper sleep in children and adolescents. Both medications are administered at bedtime or 1-2 hours before bedtime. SSRIs have been found useful for treating chronic pain states in adults.
Amitriptyline
Amitriptyline is used for analgesia for certain chronic and neuropathic pain conditions.
Imipramine (Tofranil)
These agents have been suggested to act by inhibiting reuptake of noradrenaline at synapses in central descending pain modulating pathways located in the brainstem and spinal cord.
Doxepin (Silenor)
Doxepin increases the concentration of serotonin and norepinephrine in the CNS by inhibiting their reuptake by the presynaptic neuronal membrane. It inhibits histamine and acetylcholine activity and has proven useful in the treatment of various forms of depression associated with chronic and neuropathic pain.
Nortriptyline (Pamelor)
Nortriptyline has demonstrated effectiveness in the treatment of chronic pain.
Desipramine (Norpramin)
This is the original TCA used for depression. These agents have been suggested to act by inhibiting reuptake of noradrenaline at synapses in central descending pain modulating pathways located in the brainstem and spinal cord.
Skeletal Muscle Relaxants
Class Summary
Skeletal muscle relaxants may act centrally by a selective action on the central nervous system (CNS) and are principally used for relieving painful muscle spasms or spasticity that occurs in musculoskeletal and neuromuscular disorders. Their mechanism of action may be due, in part, to their CNS-depressant activity.
Cyclobenzaprine (Flexeril)
Cyclobenzaprine helps decrease the hyperarousal mechanisms in FMS and, in turn, helps the child sleep better. It is structurally related to the tricyclic antidepressants and exhibits similar pharmacologic effects. It primarily acts on the CNS at the brainstem level.
Nonsteroidal Anti-Inflammatory Drugs and Miscellaneous Analgesics
Class Summary
NSAIDs and miscellaneous analgesics are used for their anti-inflammatory, analgesic, and antipyretic effects. They are useful for the relief of mild-to-moderate pain.
Ibuprofen (Advil, Motrin)
Ibuprofen may help achieve analgesia when used in combination with skeletal muscle relaxants or tricyclic antidepressants. It inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
Ketoprofen
Ketoprofen is used for relief of mild to moderate pain and inflammation. Small dosages initially are indicated in small and elderly patients and in those with renal or liver disease. Doses greater than 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe the patient for response.
Naproxen (Aleve, Anaprox, Naprosyn)
Naproxen is used for relief of mild to moderate pain; it inhibits inflammatory reactions and pain by decreasing the activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis. NSAIDs decrease intraglomerular pressure and decrease proteinuria.
Acetaminophen (Tylenol, FeverAll, Tempra)
Acetaminophen is the drug of choice for pain in patients with documented hypersensitivity to aspirin or NSAIDs, patients with upper gastrointestinal disease, or those who are taking oral anticoagulants.
Anthony KK, Schanberg LE. Juvenile primary fibromyalgia syndrome. Curr Rheumatol Rep. Apr 2001;3(2):165-71. [Medline].
Bennett RM. The fibromyalgia syndrome. In: Textbook of Rheumatology. 5th ed. Philadelphia, PA: WB Saunders Co; 1997:511-9.
Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. Jun 2008;37(6):339-52. [Medline].
Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. Jun 2007;36(6):339-56. [Medline].
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. Jan 1995;38(1):19-28. [Medline].
Romano TJ. Fibromyalgia in children; diagnosis and treatment. W V Med J. Mar 1991;87(3):112-4. [Medline].
Buskila D, Press J, Gedalia A. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol. Feb 1993;20(2):368-70. [Medline].
Kashikar-Zuck S, Graham TB, Huenefeld MD, Powers SW. A review of biobehavioral research in juvenile primary fibromyalgia syndrome. Arthritis Care Res. Dec 2000;13(6):388-97. [Medline].
Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum. Feb 1985;28(2):138-45. [Medline].
Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up. Pediatrics. Mar 1998;101(3 Pt 1):377-82. [Medline].
Buskila D, Neumann L, Hershman E. Fibromyalgia syndrome in children--an outcome study. J Rheumatol. Mar 1995;22(3):525-8. [Medline].
Gedalia A, Garcia CO, Molina JF; Bradford NJ; Espinoza LR. Fibromyalgia syndrome: experience in a pediatric rheumatology clinic. Clin Exp Rheumatol. May-Jun 2000;18(3):415-9. [Medline].
Tayag-Kier CE, Keenan GF, Scalzi LV. Sleep and periodic limb movement in sleep in juvenile fibromyalgia. Pediatrics. Nov 2000;106(5):E70. [Medline].
Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. Oct 2003;48(10):2923-30. [Medline].
Neumann L, Smythe HA, Buskila D. Performance of point count and dolorimetry in assessing nonarticular tenderness in children. Arthritis and Rheumatism. 1989;28(2):138-145.
Calabro JJ. Fibromyalgia (fibrositis) in children. Am J Med. Sep 29 1986;81(3A):57-9. [Medline].
Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. Nov 1996;39(11):1852-9. [Medline].
Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. Sep 2008;9(9):792-805. [Medline].
Rossy LA, Buckelew SP, Dorr N, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. Spring 1999;21(2):180-91. [Medline].
Degotardi PJ, Klass ES, Rosenberg BS, et al. Development and evaluation of a cognitive-behavioral intervention for juvenile fibromyalgia. J Pediatr Psychol. Aug 2006;31(7):714-23. [Medline].
McLoughlin MJ, Stegner AJ, Cook DB. The relationship between physical activity and brain responses to pain in fibromyalgia. J Pain. Jun 2011;12(6):640-51. [Medline]. [Full Text].
Walco GA, Ilowite NT. Cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol. Oct 1992;19(10):1617-9. [Medline].
Kashikar-Zuck S, Vaught MH, Goldschneider KR, et al. Depression, coping, and functional disability in juvenile primary fibromyalgia syndrome. J Pain. Oct 2002;3(5):412-9. [Medline].
Print
